HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Mistry, G. C. Articles by Herman, G. A. Search for Related Content PubMed PubMed Citation Articles by Mistry, G. C. Articles by Herman, G. A.

Multiple-Dose Administration of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Alter the Single-Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects

From Merck & Co, Inc, Whitehouse Station, New Jersey (Mr Mistry, Dr Bergman, Dr Luo, Dr Davies, Dr Gottesdiener, Dr Wagner, Dr Herman); Merck & Co, Inc, Brussels, Belgium (Ms Cilissen); and SGS Life Sciences Services, Antwerp, Belgium (Dr Haazen).

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an incretin enhancer that is approved for the treatment of type 2 diabetes. Sitagliptin is mainly renally eliminated and not a potent inhibitor of CYP450 enzymes in vitro. Rosiglitazone, a thiazolidenedione, is an insulin sensitizer and mainly metabolized by CYP2C8. Since both agents may potentially be coadministered, the purpose of this study was to examine the effects of sitagliptin on rosiglitazone pharmacokinetics. In this open-label, randomized, 2-period, crossover study, 12 healthy normoglycemic subjects, 21 to 44 years, received single 4-mg doses of rosiglitazone alone in one period and coadministered with sitagliptin on day 5 following a multiple-dose regimen for sitagliptin (200 mg once daily x 5 days) in the other period. The geometric mean ratios and 90% confidence intervals ([rosiglitazone + sitagliptin]/rosiglitazone) for rosiglitazone AUC_0- and C_max were 0.98 (0.93, 1.02) and 0.99 (0.88, 1.12), respectively. In conclusion, sitagliptin did not alter the pharmacokinetics of rosiglitazone in healthy subjects.

Key Words: MK-0431 • sitagliptin • DPP-4 • pharmacokinetics • rosiglitazone

Address for reprints: Address for correspondence: Gary A. Herman, MD, Merck Research Laboratories, Mail Code RY34-A536, PO Box 2000, Rahway, NJ 07065-0900.

This article has been cited by other articles:

				D. Q. Pham, A. Nogid, and R. Plakogiannis Sitagliptin: A novel agent for the management of type 2 diabetes mellitus Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 521 - 531. [Abstract] [Full Text] [PDF]